VAUGHAN, Ontario, May 21, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow:
Name For Against Broker Non-Votes Nathalie Bernier 337,617,248 1,924,336 8,383,437 Gary Hu 337,591,706 1,949,878 8,383,437 Brett Icahn 337,474,287 2,067,297 8,383,437 Sarah B. Kavanagh 337,602,211 1,939,373 8,383,437 Karen L. Ling 337,526,114 2,015,470 8,383,437 John A. Paulson 337,650,735 1,890,849 8,383,437 Russel C. Robertson 337,600,880 1,940,704 8,383,437 Thomas W. Ross, Sr. 337,583,018 1,958,566 8,383,437 Brenton L. Saunders 337,592,062 1,949,522 8,383,437 Andrew C. von Eschenbach, M.D. 337,607,276 1,934,308 8,383,437
Shareholders also approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers, appointment of PricewaterhouseCoopers LLP to serve as auditor until the close of the Company's 2026 Annual Meeting of Shareholders, and authorization for the board of directors to fix the auditor’s remuneration.
The final vote tabulation on all matters voted on at the Annual Meeting will be filed with the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company’s website at www.bausch.com.
About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.
Story Continues
View source version on businesswire.com: https://www.businesswire.com/news/home/20250521597609/en/
Contacts
Media Contact:
Chris Clark
[email protected]
(848) 360-1100
Investor Contact:
George Gadkowski
[email protected]
(877) 354-3705 (toll free)
(908) 927-0735
View Comments
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...